Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Reports Stock Transactions

CEO Jeremy Bender reports acquisition and disposal of Day One Biopharmaceuticals stock, including transactions related to tax liabilities and vesting of Restricted Stock Units (RSUs).

Summary

• Jeremy Bender, CEO of Day One Biopharmaceuticals, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On May 15, 2025, Bender acquired common stock through the vesting of Restricted Stock Units (RSUs).
• Specifically, 3,562, 4,750, 11,687 and 11,687 shares were acquired through RSU vesting.
• On May 16, 2025, Bender disposed of 13,964 shares of common stock at a weighted average price of $6.2579 per share to cover tax liabilities related to the RSU settlement.
• Following these transactions, Bender directly owns 145,737 shares of common stock.
• Bender also indirectly owns shares through various grantor retained annuity trusts and a revocable trust, totaling 1,609,438 shares.
• The RSUs vest in quarterly installments and do not expire.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The vesting of RSUs indicates continued service and commitment of the CEO to the company.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it's a common practice.

Risks

• Significant stock ownership by insiders could lead to concerns about potential conflicts of interest or influence on company decisions.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the specifics of these transactions (e.g., RSU vesting, tax-related sales) are typical.
• Comparing the size and frequency of insider transactions at Day One Biopharmaceuticals to those of similar-sized biotech companies (e.g., comparable market cap and stage of development) would provide a more contextualized assessment.
• For example, companies like Relay Therapeutics or Black Diamond Therapeutics could serve as benchmarks for evaluating the relative significance of Bender's transactions.

Stakeholder Impact

• The transactions could have a minor impact on shareholders' perception of the company, depending on how they interpret the insider activity.
• Employees holding RSUs may be interested in the vesting schedule and tax implications.

Key Dates

Keywords

Form 4, beneficial ownership, Jeremy Bender, Day One Biopharmaceuticals, DAWN, Restricted Stock Units, RSU, stock transactions, insider trading